Teva’s Version of Neupogen Approved by FDA

The US FDA (Food and Drug Administration) have approved Teva Pharmaceutical Industries’ form of Amgen’s severe neutropenia therapy, Neupogen. The FDA have approved tbo-filgrastim, which Teva noted is the first new granulocyte colony-stimulating factor (G-CSF) to be backed by the US agency in over 10 years.  The drug is a copy of Neupogen (filgrastim), which

Continue Reading

Teva Won’t Launch Generic Lipitor in US

Teva Pharmaceuticals have decided not to retail atorvastatin, a generic version of Pfizer’s blockbuster cholesterol medication Lipitor, in the US. In December 2011, the Israeli drug maker signed an agreement with Ranbaxy Laboratories to help Ranbaxy during the 180-day exclusivity period they had to sell their copycat version of Lipitor (atorvastatin).  The agreement has resulted

Continue Reading

FDA Approves Teva’s Generic Version of Lipitor

Generics major Teva Pharmaceutical Industries is set to enter the lucrative market created in the USA by the patent expiry on Pfizer’s Lipitor but not until Ranbaxy Laboratories’ 180-day exclusivity period runs out. The Israeli drugmaker noted that the US FDA (Food and Drug Administration) have granted tentative approval for their generic version of Lipitor,

Continue Reading